A survey of the prescription of the novel anticonvulsants lrunotrigine, vigabatrin, gabapentin and topiramate was carried out in an outpatient setting to investigate the outcome of prescription and factors affecting response. One hundred and fifty randomly selected patient notes were analysed retrospectively. Drug continuation and seizure freedom were used as measures of response. Twenty-nine percent of patients had a brain lesion, 14% a psychiatric disorder, 7% neonatal seizures, 21% a family history of epilepsy and 15% a learning disability. On average at the moment of initiation of the novel anticonvulsant the patients had had a diagnosis of epilepsy for 18 years, were 33 years old, had 19 seizures per month and had previously used two drugs which failed to control their epilepsy. The first novel anticonvulsant was in 55% of cases lamotrigine, in 43% vigabatrin and in 1% gabapentin. The overall percentage of patients who stayed on their first novel anticonvulsant was 55%, and 17% became seizure-free. No factors were found to influence the response in terms of drug continuation. For seizure freedom, the presence of a psychiatric disorder and partial seizures predicted a significantly poorer response. Length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of chugs previously used were all significantly lower in the seizure-free group.
INTRODUCTION
Four novel anticonvulsant drugs, vigabatrin, lamotrigine, gabapentin and topiramate, have been introduced in the UK in 1989 UK in , 1992 UK in , 1994 UK in and 1996 , respectively. These new drugs are indicated for add-on treatment of partial and secondary generalized (tonicclonic) seizures which are inadequately controlled by the standard antiepileptic drugslA. This indication includes up to 30% of the population with epilepsy5. With additional indications, in the case of lamotrigine, for monotherapy and the treatment of Lennox Gastaut syndrome.
In a review of the randomized controlled trials of add-on treatments with these drugs, they were concluded to be significantly better than placebos at reducing seizure frequency, but a conclusive indication of difference in efficacy and tolerability could not be found6v7. In addition, the question still remains as to whether the new antiepileptic drugs affect the long-term prognosis of refractory epilepsy8*9. Walker et al8 showed that after 6-8 years of follow-up, of 253 patients with severe refractory epilepsy who participated in a trial of add-on treatment of vigabatrin or lamotrigine, 73% were withdrawn from their trial drugs and only 1% became seizure-free'. However, no investigation of patient characteristics affecting these outcome measures was carried out.
In order to address this problem, we undertook a study to investigate, first, the outcome of the prescription of novel anticonvulsants in an outpatient setting and, second, to elucidate factors which may predict response to novel anticonvulsant medication.
MATERIALS AND METHODS
All the patients in this study were referred to the Epilepsy Unit of the University Hospital of Wales, Cardiff, Wales, UK. This unit is both a specialist re-0 1998 British Epilepsy Association ferral centre for patients with epilepsy in Wales and a direct referral centre for primary care physicians. Data were obtained by review of the notes. A non-biased randomized method was used for sampling the notes. A pilot study of 15 notes was performed to verify the methodology. Of the 2560 patients' notes held in the unit, 640 were studied. Patients were included in the study if they had used at least one of the novel anticonvulsants vigabatrin, lamotrigine, gabapentin or topiramate. They had to have used the drugs for at least 3 months, unless withdrawn within this period, to be included in the study.
Our outcome measures of response were continuation of the drug and seizure freedom. Seizure freedom was recorded if a patient did not have a seizure for a period longer than 3 months until the end of follow-up.
The following patient characteristics were predicted to have an influence on the outcome: age at initiation, age at first seizure, length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs prescribed, as well as type of seizure disorder (primary generalized epilepsy or partial epilepsy), sex, the presence of a psychiatric disorder, learning disability, a structural brain lesion, neonatal seizures and a family history of epilepsy.
If no mention was made of the latter factors, they were considered to be absent. Seizure frequency was recorded as the number of seizures per month. The recording of a family history of epilepsy was restricted to first-and second-degree relatives. A structural brain lesion was defined as a deformity of the brain which presumably generates the epileptic activity.
All previously prescribed 'classic' anticonvulsants, as well as the maximum daily dosages reached, were recorded. If a novel anticonvulsant was withdrawn the reason for withdrawal and the time period the drug was used for were recorded.
Statistics
Data were coded and analysed on SPSS for Windows. chi-squared statistics were used to compare the effects of dichotomous variables. The non-parametric MannWhitney U-test (or the Wilcoxon signed-rank test) was applied to compare continuous variables.
RESULTS

Patient characteristics
A total of 150 patients (81 female, 69 male) from the 640 notes (23%) were found to have had a novel anticonvulsant prescribed. The mean age of the patients R. D. Thijs et a/ was 38 years (SD = 13). The majority of the patients had partial seizures with secondary generalization (56%), 25% a primary generalized disorder and 18% partial seizures without secondary generalization.
Twenty-nine percent of patients had a brain lesion, 14% a psychiatric disorder, 7% neonatal seizures, 2 1% a family history of epilepsy and 15% a learning disability. Of the 43 patients with a brain lesion, eight had suffered head injury, seven meningitis or encephalitis, five birth trauma, five a brain tumour, four hydrocephalus, three had developed epilepsy following neurosurgery, two an arteriovenous malformation, two a cerebrovascular accident, two microcephalus, two temporal sclerosis, one multiple sclerosis, one an arachnoid cyst and one a cerebral abscess.
Of the 21 patients with a psychiatric disorder, 11 suffered from depression, five from an anxiety disorder, one a bipolar disorder, two alcoholism, one a schizoaffective disorder, and one a borderline personality.
The average age at first seizure was 15 years. On average, at the moment of initiation of the novel anticonvulsant the patients had had a diagnosis of epilepsy for 18 years, were 33 years old and had 19 seizures per month (median = 6). Of the 123 patients who had their seizure frequency recorded, 20% had more than one seizure per day, 44% had one to six seizures per week, 25% one to three a month, 2% one to 11 a year and 7% of the patients were seizure-free at moment of initiation. The patients had used, on average, two drugs previously that had failed to control their epilepsy.
Previous anticonvulsants included carbamazepine (89%), valproate (81%), phenytoin (60%), primidone (290/o), phenobarbitone (27%), clobazam (16%), clonazepam (11%) and ethosuximide (9%).
The first novel anticonvulsant was in 55% of cases lamotrigine, 43% vigabatrin and 1% gabapentin. Figure 1 depicts the distribution of lamotrigine, vigabatrin, gabapentin and topiramate in relation to the order these drugs were prescribed. The mean number of novel anticonvulsants prescribed was 1.6.
As a first-order novel anticonvulsant 76% (n = 38) of the patients with primary generalized epilepsy reOrder of new anticonvulsant ceived lamotrigine and 24% (n = 38) vigabatrin. Of the patients with partial or secondary generalized seizures 50% received vigabatrin as a first-order drug, 48% lamotrigine and 2% gabapentin.
Response
The overall percentage of patients who stayed on their first novel antiepileptic drug was 55%, and 56% (n = 63) of patients stayed on their second novel drug. Figure 2 shows the frequency of withdrawal and continuation of the drug in relation to the order of prescription. Reasons for withdrawal were lack of efficacy 55% (n = 66), side effects 36% (n = 66), patient initiated 8% (n = 66) and seizure freedom 1% (n = 66). first drug, 65% (n = 68) received a second novel anticonvulsant and 23% (n = 82) of the patients who stayed on their first drug received a second novel anticonvulsant.
Of the group of patients who continued on the first novel drug, 32% (n = 19) stayed on their second novel anticonvulsant and 66% (n = 44) of the group who were withdrawn from their first drug stayed on their second novel anticonvulsant. The introduction of a second novel anticonvulsant gave a significantly poorer response when the first drug was not withdrawn (chisquared statistics, P = 0.01). Seventeen percent of patients were seizure-free for at least 3 months on their first novel anticonvulsant and 8% (n = 63) on their second drug.
Predictors of response Drug continuation
Dichotomous variables, type of seizure disorder, sex, psychiatric disorder, learning disability, structural brain lesion, neonatal seizures and a family history of epilepsy all had no significant influence on drug withdrawal. The response rates for patients with a brain lesion, learning disability, psychiatric disorder and partial or primary generalized seizure disorder are summarized in Table 1. Table 2 summarizes the mean and median values of these variables in the groups of patients who stayed on their first new drug and patients who were withdrawn from their first novel anticonvulsant. None of the tests comparing age at initiation, age at first seizure, the length of seizure disorder at initiation, seizure frequency, previously used failed drugs and total number of drugs used, proved to be significant. Table 3 summarizes the mean and median values of these variables in the groups of patients who stayed on the first novel anticonvulsant and in those who were withdrawn from their first drug. The introduction of a second novel anticonvulsant gave a significantly poorer response when the first was not withdrawn (chi-squared statistics, P = 0.01). 4.4 4 4.1 4 Statistical analysis did not reveal any significant changes for these factors within responding and non-responding patients (Mann-Whitney U-test, P = 0.05). The mean time of follow-up of the patients staying on the drug was 4.4 years. 3.2 3.5 4.5 4 *The length of seizure disorder, the seizure Frequency at initiation, the number of previous failed drugs and the total number of drugs prescribed were all significantly lower in the group of patients who became seizure-free Mann-Whitney U-test, previous failed drugs P = 0.01, all other P-values ~0.001).
Seizure freedom P = 0.002, respectively). The other dichotomous factors, sex, neonatal seizures, brain lesion, learning disThe absence of a psychiatric disorder and the presence of a primary generalized seizure disorder gave a significantly higher percentage of patients becoming seizure-free (&i-squared statistics P = 0.02 and ability, family history of epilepsy, had no significantly different effects on seizure freedom. The presence of a positive family history revealed a trend which approached significance (P = O.O53).The response rates for these patients are summarized in Table 1 .
The length of seizure disorder, the seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs prescribed were all significantly lower in the group of patients who became seizure-free (previously used failed drugs P = 0.01, all other P values t0.001). Table 3 summarizes the mean and median values of these variables in the groups of patients who still have fits and in those who became seizure-free.
DISCUSSION
In this study we found no specific factors predicting response as defined by drug continuation. For seizure freedom, the presence of a psychiatric disorder and seizures of partial origin were seen to have a significantly poorer response. The length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs were all significantly lower in the group of patients who became seizure-free.
Our population is representative for patients with refractory epilepsy treated in a specialist centre for epilepsy. Compared with the general population attending an epilepsy clinic, our study population has a higher morbidity lo. In a review of a population attending an epilepsy clinic, 17% of the patients had what we defined as a structural brain lesion, 6% a mental handicap and 50% of the patients had their seizures controlled by regular treatmentlO.
Our sample of 150 patients proved to be large enough to find several discernible effects in the group of seizure-free patients, though we must take into account that the other effects could be significant in a larger population.
There are several ways of defining response' '. In this study we chose seizure freedom and drug continuation, as these are two objective and definitive measures of success. In contrast to a previous study which found that after 6-8 years 27% of the patients were still on lamotrigine or vigabatrin and 1% became seizure-free', we found that a higher percentage (55%) of the patients continued their first novel anticonvulsant and 17% became seizure-free. As in this previous study seizure freedom was not defined and the morbidity of the population was ill-defined, we cannot compare our results with theirs. Nevertheless, these results appear to indicate that morbidity is an important factor influencing the success of new drugs.
All the factors which appeared as trends affecting drug continuation proved to be more marked and sometimes significant when applied to our second outcome measure, seizure freedom. The presence of a learning disability was the only exception to this pattern. For with drug continuation, patients with a learning disability had a higher response, whereas their achievement of seizure freedom was significantly poorer. We suggest this discrepancy may relate to the special caring situation of these patients.
The drug continuation of the second novel anticonvulsant was significantly poorer when the first novel anticonvulsant was continued. The drug removal curve illustrates that the decline in the percentage of patients staying on the drug with time is faster in the patients receiving a second drug.
The finding of a poorer response within the group of patients with partial epilepsy agrees with a previous finding in the general population of patients with epilepsy' l.
Although we think this retrospective analysis requires cautious interpretation, it nevertheless provides useful information on the prescription of novel anticonvulsants in an outpatient setting and shows trends which may predict response to the new anticonvulsant medications.
